Deliver Your News to the World

CybeRelease: (OTC: MNCL) Reports Agreement with Novolypharma of Spain


(CybeRelease, January 29, 2007) - Lake Harmony, PA - Martin Nutraceuticals Inc. (OTC PK: MNCL) is pleased to announce it is now in the final stages of an agreement with Novolypharma, out of Madrid, Spain. The agreement will not only provide for the production of its flagship products, but will also allow Martin Nutraceuticals to acquire the distribution rights for various Novolypharma products.

Novolypharma is a nutraceutical laboratory with the most advanced level of technology currently available in the nutraceutical manufacturing field, allowing it to conform to FDA (Pharmaceutical) Standards. Novolypharma is majority owned by X Consul Group Company, is a very well respected conglomerate in the nutraceutical marketplace, which includes companies such as CIMA 27, Ydosis and Kapal Consulting.

X Consul Global Company maintains the rights for the worldwide licensing of Novolypharma products, which includes the CGY 25 plant extract that promotes prostate and sexual health substantiated by scientific research conducted by the Montpelier University of France and the University of Seoul of South Korea.

“We are very excited about finalizing this agreement with Novolypharma and X Consul Global,” states Mr. Harvey Panesar, President of Martin Nutraceuticals Inc., “this is a great boost for our current products as well the products that are being developed. Not only will we be with a FDA approved laboratory, we will also have access to many of Novolypharma’s products, allowing us to maintain our quality of products and expand our product line. Getting ready for our US launch of the Infomercial and the products, we felt strongly about aligning ourselves with a GMP and FDA approved lab, which is what Novolypharma provides us.”
About Martin Nutraceuticals Inc.

Martin Nutraceuticals Inc. is a company focused on providing a better health and lifestyle through natural products. Martin Nutraceuticals flagship products include Arthrizyme(TM) for general joint pain and Oxygenol(TM) for anti-oxidation and Maximum Slim(TM) for weight control.

Arthrizyme(TM) is a unique blend of systemic enzymes proven to rapidly reduce inflammation in joints and muscles. Arthrizyme(TM) is not limited to anti-inflammatory effects; it also assists the body in the healing process by breaking down fibrin in joints and muscles. Arthrizyme(TM) differs from all other natural arthritis remedies and was designed to work for all types of arthritis and in all joints of the body. Arthrizyme(TM) is fast acting, usually improving symptoms within the first few days.

To read the complete release, go to

For a Free Newsletter, go to

CybeRelease Gainers are Extreme Networks, Inc. (Nasdaq: EXTR), VistaPrint Limited (Nasdaq: VPRT), Packeteer, Inc. (Nasdaq: PKTR), Columbia Sportswear Company (Nasdaq: COLM), ABAXIS, Inc. (Nasdaq: ABAX), CyberSource Corporation (Nasdaq: CYBS), SunPower Corporation (Nasdaq: SPWR) and Kosan Biosciences Incorporated (Nasdaq: KOSN).

CybeRelease Decliners are Synaptics Incorporated (Nasdaq: SYNA), CDW Corporation (Nasdaq: CDWC), ANADIGICS, Inc. (Nasdaq: ANAD), Arotech Corporation (Nasdaq: ARTX), Diversa Corporation (Nasdaq: DVSA), Natural Health Trends Corporation (Nasdaq: BHIP), Pointer Telocation Ltd. (Nasdaq: PNTR) and Hi-Tech Pharmacal Co., Inc. (Nasdaq: HITK).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid CybeRelease $500.00 for the publication of this report. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation and do no trading of any kind.


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.